Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.52 USD
+0.01 (2.94%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.52 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Earnings News For SGMO
-
Sangamo: Q4 Earnings Snapshot
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Sangamo: Q3 Earnings Snapshot
-
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
-
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
-
Sangamo: Q2 Earnings Snapshot
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
-
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
-
Sangamo: Q4 Earnings Snapshot
-
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
-
Sangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
-
Sangamo: Q3 Earnings Snapshot
-
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
-
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates
-
Sangamo: Q2 Earnings Snapshot
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
-
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
-
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
-
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates
-
Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline
-
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
-
Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline